| The tyramine binding site in the central nervous system: an overview. | |
| | |
MedLine Citation:
|
PMID: 8396735 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The [3H]Tyramine (TY) binding site is proposed as a high affinity marker of the membrane carrier for dopamine (DA) in synaptic vesicles from DA-rich brain regions. Under precise assay conditions, there is neither a consistent association of TY with the neuronal, cocaine-sensitive DA transporter, nor with mitochondrial or microsomal targets. TY-labeled sites have a high affinity for selected toxins such as the Parkinsonian agent MPP+ (1-methyl-4-phenylpyridinium ion), or drugs such as diphenylalkylamine Ca(2+)-channel antagonists. The MPP+/TY site interaction, which in the striatum leads to depletion of vesicular DA, occurs in dopaminergic as well as in noradrenergic regions, though with different kinetic profiles. TY-labeled carriers for DA and noradrenaline (NA) in respective vesicles seem to be different entities, which might result in a region-specific rate of toxin sequestration and/or release from heterogeneous vesicles. Whereas MPP+ is a potent competitive-type inhibitor of [3H]TY binding, prenylamine-like Ca(2+)-channel antagonists can compete with TY for the vesicle site, in a tetrabenazine- or reserpine-like manner, and also inhibit TY binding thanks to the extra-channel directed impairment of membrane bioenergetics they are proposed to provoke. This follows from the generally-accepted assumption that similar mechanisms are operational for secretory organelles in adrenals and CNS, and from the marked sensitivity of TY binding to miscellaneous energy-disrupting agents.(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
A Vaccari |
Related Documents
:
|
12112405 - Parametric mapping of [18f]fpcit binding in early stage parkinson's disease: a pet study. 16392815 - Design and synthesis of photoaffinity-labeling ligands of the l-prolyl-l-leucylglycinam... 23271735 - Alteration of tropomyosin-binding properties of tropomodulin1 affects its capping abili... 23192025 - Complex of myoglobin with phenol bound in a proximal cavity. 12221095 - Specific molecular interactions of oversulfated chondroitin sulfate e with various hepa... 8879835 - Serum cortisol binding capacity measured with concanavalin a-sepharose in patients with... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Neurochemical research Volume: 18 ISSN: 0364-3190 ISO Abbreviation: Neurochem. Res. Publication Date: 1993 Aug |
Date Detail:
|
Created Date: 1993-10-08 Completed Date: 1993-10-08 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 7613461 Medline TA: Neurochem Res Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 861-8 Citation Subset: IM |
Affiliation:
|
Department of Neuroscience, B. Brodie, Cagliari, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
/
pharmacology Animals Binding Sites Brain / metabolism* Calcium Channel Blockers / pharmacology Dopamine / metabolism Humans Receptors, Biogenic Amine* Receptors, Neurotransmitter / drug effects, metabolism* Tyramine / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Calcium Channel Blockers; 0/Receptors, Biogenic Amine; 0/Receptors, Neurotransmitter; 0/tyramine receptor; 28289-54-5/1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 51-67-2/Tyramine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes.
Next Document: Electric shock convulsions in the rabbit and brain cortex GABAA receptor function.